share_log

Apollomics | F-3/A: Registration statement for specified transactions by certain foreign private issuers (Amendment)

Apollomics | F-3/A: Registration statement for specified transactions by certain foreign private issuers (Amendment)

Apollomics | F-3/A:交易註冊聲明(修正)
美股sec公告 ·  04/20 04:11
牛牛AI助理已提取核心訊息
Apollomics Inc., a biopharmaceutical company based in the Cayman Islands, has filed an amendment to its Form F-3 registration statement with the U.S. Securities and Exchange Commission (SEC) on April 19, 2024. The company, which specializes in the discovery and development of oncology therapies, is preparing for the proposed sale of securities to the public, which will commence after the effectiveness of the registration statement. The securities may include Class A Ordinary Shares, Debt Securities, Rights, Warrants, and Units, with a total offering amount of up to $200,000,000. Apollomics Inc. has its principal executive offices in Foster City, California, and operates through its U.S. headquarters and subsidiaries in mainland China. The company's Class A Ordinary Shares and warrants are listed...Show More
Apollomics Inc., a biopharmaceutical company based in the Cayman Islands, has filed an amendment to its Form F-3 registration statement with the U.S. Securities and Exchange Commission (SEC) on April 19, 2024. The company, which specializes in the discovery and development of oncology therapies, is preparing for the proposed sale of securities to the public, which will commence after the effectiveness of the registration statement. The securities may include Class A Ordinary Shares, Debt Securities, Rights, Warrants, and Units, with a total offering amount of up to $200,000,000. Apollomics Inc. has its principal executive offices in Foster City, California, and operates through its U.S. headquarters and subsidiaries in mainland China. The company's Class A Ordinary Shares and warrants are listed on the Nasdaq Capital Market under the symbols 'APLM' and 'APLMW,' respectively. As of April 17, 2024, the closing prices for the shares and warrants were $0.53 and $0.02, respectively. The company has not yet made any dividends or distributions to its parent companies or investors, and the transfer of funds between the company and its subsidiaries is subject to PRC government controls on currency conversion.
總部位於開曼群島的生物製藥公司Apollomics Inc. 已於2024年4月19日向美國證券交易委員會(SEC)提交了其F-3表格註冊聲明的修正案。該公司專門從事腫瘤療法的發現和開發,正在爲擬議的向公衆出售證券做準備,該計劃將在註冊聲明生效後開始。這些證券可能包括A類普通股、債務證券、權利、認股權證和單位,總髮行金額高達2億加元。Apollomics Inc. 的主要執行辦公室位於加利福尼亞州的福斯特城,並通過其美國總部和中國大陸的子公司開展業務。該公司的A類普通股和認股權證分別以'APLM'和'APLMW'的代碼在納斯達克資本市場上市。截至2024年4月17日,股票和認股權證的收盤價分別爲0.53美元和0.02美元。該公司尚未向其母公司或投資者派發任何股息或分配,公司與其子公司之間的資金轉移受中國政府的貨幣兌換管制。
總部位於開曼群島的生物製藥公司Apollomics Inc. 已於2024年4月19日向美國證券交易委員會(SEC)提交了其F-3表格註冊聲明的修正案。該公司專門從事腫瘤療法的發現和開發,正在爲擬議的向公衆出售證券做準備,該計劃將在註冊聲明生效後開始。這些證券可能包括A類普通股、債務證券、權利、認股權證和單位,總髮行金額高達2億加元。Apollomics Inc. 的主要執行辦公室位於加利福尼亞州的福斯特城,並通過其美國總部和中國大陸的子公司開展業務。該公司的A類普通股和認股權證分別以'APLM'和'APLMW'的代碼在納斯達克資本市場上市。截至2024年4月17日,股票和認股權證的收盤價分別爲0.53美元和0.02美元。該公司尚未向其母公司或投資者派發任何股息或分配,公司與其子公司之間的資金轉移受中國政府的貨幣兌換管制。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。